The Latest Cardiac and Vascular News
DENVER, Feb. 27, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 2022 Highlights Total revenue of $102.2 million primarily from 16 revenue units including one upgrade, compared to 2021 revenue of approximately $70.1 million, primarily from ten revenue […]
Autonomous, robotic transcranial Doppler (TCD) ultrasound is a real-time neuromonitoring tool that can detect and help prevent intraprocedural complications LOS ANGELES, Feb. 28, 2023 (GLOBE NEWSWIRE) — NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, today announced the donation of a NovaGuide™ […]
Single Intra-Myocardial Intervention with Rexlemestrocel-L Reduced Cardiovascular Death, Myocardial Infarction or Stroke Over Mean Follow-Up of 30 Months in High-Risk Patients with Chronic Heart Failure NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the […]
Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, announced that its preclinical stage drug candidates […]
Q4 Revenue Up 42%; Expansion of Clinical Evidence Sets Stage for 2023 Growth MINNEAPOLIS, Feb. 28, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended […]
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended December 31, 2022. Dr. Silviu Itescu, Chief Executive of Mesoblast, commenting on the results said, “There is an […]
DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure […]
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of experience with focus on drug approval and commercialization, mergers and acquisitions, and business development MIAMI, Feb. 28, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a […]
DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, based on the preliminary voting results provided by its proxy solicitors following the Company’s 2023 General Meeting of Shareholders (the “General Meeting”), Amarin shareholders have voted to […]
PrecisionCHD™ is the First Integrated Epigenetic-Genetic-Based Blood Test for the Early Detection of Coronary Heart Disease CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. PrecisionCHD is […]
